Litcius/Paper detail

Discovery of novel and orally bioavailable CDK 4/6 inhibitors with high kinome selectivity, low toxicity and long-acting stability for the treatment of multiple myeloma

Kai Yuan, Wenbin Kuang, Weijiao Chen, Minghui Ji, Wenjian Min, Yasheng Zhu, Yi Hou, Xiao Wang, Jiaxing Li, Liping Wang, Peng Yang

2021European Journal of Medicinal Chemistry17 citationsDOIOpen Access PDF

Topics & Concepts

KinomeChemistryPotencyPharmacologyBioavailabilityDruggabilityCyclin-dependent kinaseToxicityLead compoundCyclin-dependent kinase 6Multiple myelomaDrug discoveryDrugKinaseIn vivoBiochemistryIn vitroInternal medicineBiologyMedicineCell cycleGeneOrganic chemistryBiotechnologyCellMultiple Myeloma Research and TreatmentsAdvanced Breast Cancer TherapiesChronic Lymphocytic Leukemia Research
Discovery of novel and orally bioavailable CDK 4/6 inhibitors with high kinome selectivity, low toxicity and long-acting stability for the treatment of multiple myeloma | Litcius